Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

  1. Caballero-Velázquez, T.
  2. López-Corral, L.
  3. Encinas, C.
  4. Castilla-Llorente, C.
  5. Martino, R.
  6. Rosiñol, L.
  7. Sampol, A.
  8. Caballero, D.
  9. Serrano, D.
  10. Heras, I.
  11. San Miguel, J.
  12. Pérez-Simón, J.A.
Zeitschrift:
British Journal of Haematology

ISSN: 0007-1048 1365-2141

Datum der Publikation: 2013

Ausgabe: 162

Nummer: 4

Seiten: 474-482

Art: Artikel

DOI: 10.1111/BJH.12410 GOOGLE SCHOLAR